<div id="readability-page-1"><p>Stempoint Capital LP bought a new stake in shares of  Cidara Therapeutics, Inc. (NASDAQ:CDTX - Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The fund bought 266,774 shares of the biotechnology company's stock, valued at approximately $12,995,000. Cidara Therapeutics makes up   4.2% of Stempoint Capital LP's portfolio, making the stock its 8th largest position. Stempoint Capital LP owned about 1.05% of Cidara Therapeutics at the end of the most recent reporting period.</p><div><p><span></span><span>Get <strong>Cidara Therapeutics</strong> alerts:</span></p></div><ul><li>Merck Writes a $9.2 Billion Check for a Flu Drug That Could Change Everything</li></ul><p>A number of other institutional investors also recently added to or reduced their stakes in the stock. Amalgamated Bank acquired a new stake in shares of  Cidara Therapeutics in the second quarter valued at $28,000.  Trifecta Capital Advisors LLC bought a new stake in  Cidara Therapeutics during the 2nd quarter worth about $49,000.  Legal &amp; General Group Plc acquired a new stake in  Cidara Therapeutics in the 2nd quarter valued at about $73,000.  Ameritas Investment Partners Inc. acquired a new stake in  Cidara Therapeutics in the 2nd quarter valued at about $83,000.  Finally, Police &amp; Firemen s Retirement System of New Jersey bought a new position in shares of  Cidara Therapeutics in the second quarter worth about $184,000. 35.82% of the stock is owned by institutional investors and hedge funds. </p><h2>Insider Buying and Selling</h2><p>In other news, insider Nicole Negar Davarpanah sold 474 shares of the business's stock in a transaction dated Thursday, September 11th. The stock was sold at an average price of $62.86, for a total value of $29,795.64. Following the transaction, the insider directly owned 31,418 shares of the company's stock, valued at $1,974,935.48. The trade was a 1.49% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this link. Company insiders own  7.64% of the company's stock. </p><h2>Analyst Upgrades and Downgrades</h2><ul><li>Biotech Catalyst Alert: NKTR, CDTX &amp; WGS Rallying With Big Gains</li></ul><p>A number of analysts recently weighed in on the stock. Needham &amp; Company LLC lowered shares of Cidara Therapeutics from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Friday, November 14th. Wall Street Zen lowered Cidara Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday, November 8th. WBB Securities boosted their target price on Cidara Therapeutics from $123.00 to $199.00 and gave the stock a &#34;strong-buy&#34; rating in a research report on Thursday, October 9th. JMP Securities  set a $173.00 price target on Cidara Therapeutics and gave the company a &#34;market outperform&#34; rating in a research note on Friday, October 3rd. Finally, HC Wainwright cut Cidara Therapeutics from a &#34;buy&#34; rating to a &#34;neutral&#34; rating in a report on Friday, November 14th. One research analyst  has rated the stock with a Strong Buy rating, four have issued  a Buy rating, six have assigned  a Hold rating and one  has issued  a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of &#34;Hold&#34; and an average target price of $156.11.</p><p><b>Get Our Latest Analysis on Cidara Therapeutics</b></p><h2>Cidara Therapeutics Price Performance</h2><p>CDTX stock opened at $220.29 on Wednesday. The stock has a market capitalization of $6.93 billion, a price-to-earnings ratio of -18.70 and a beta of 1.46. Cidara Therapeutics, Inc. has a fifty-two week low of $15.22 and a fifty-two week high of $221.20. The business's fifty day moving average price is $145.12 and its two-hundred day moving average price is $85.96. </p><p>Cidara Therapeutics (NASDAQ:CDTX - Get Free Report) last released its earnings results on Thursday, November 6th. The biotechnology company reported ($1.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.19) by ($0.24).  Research analysts expect that  Cidara Therapeutics, Inc. will post -8.74 EPS for the current year. </p><h2>Cidara Therapeutics Company Profile</h2> (Free Report)<p>Cidara Therapeutics, Inc, a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.</p><h2>Read More</h2><ul><li>Five stocks we like better than Cidara Therapeutics</li><li>Dividend King Proctor &amp; Gamble Is A Buy On Post-Earnings Weakness </li><li>Insiders Are Selling These 3 Stocks—Here’s Why</li><li>Stock Dividend Cuts Happen Are You Ready?</li><li>Consumers Got Coal, But Santa Dropped Off Big Gains for These 2 Retailers</li><li>Energy and Oil Stocks Explained</li><li>10X Gains? These 3 Robotics Stocks Could Explode by 2035</li></ul><p><strong>Want to see what other hedge funds are holding CDTX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cidara Therapeutics, Inc. (NASDAQ:CDTX - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0RUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0RUWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Cidara Therapeutics Right Now?</h2><p>Before you consider Cidara Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cidara Therapeutics wasn't on the list.</p><p>While Cidara Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CDTX

<p>Stempoint Capital LP acquired 266,774 shares of Cidara Therapeutics, valued at $12,995,000, making it 4.2% of their portfolio. Analysts have mixed ratings on CDTX, with a strong buy, buy, hold, and sell ratings. The stock opened at $220.29, with a market cap of $6.93 billion. Cidara focuses on therapies for serious diseases, including antifungal treatments.</p>

Stempoint Capital LP Takes Position in Cidara Therapeutics, Inc. $CDTX